| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments | 1 | Pharmaceutical Technology | ||
| ONO PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 06.08. | Mediar and Ono to Develop Novel Treatments Targeting Fibro-Inflammatory Diseases | 1 | Contract Pharma | ||
| 31.07. | Ono Pharmaceutical GAAP EPS of ¥ 51.38, revenue of ¥ 116.1B | 1 | Seeking Alpha | ||
| 31.07. | Ono Pharmaceutical Co Ltd. Q1 Income Advances | 1 | RTTNews | ||
| 27.07. | Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline | 4 | Zacks | ||
| 27.07. | Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength? | 1 | Zacks | ||
| 28.05. | Jefferies raises Ono Pharmaceutical price target on pipeline outlook | 3 | Investing.com | ||
| 08.05. | Ono Pharmaceutical reports FY results | 5 | Seeking Alpha | ||
| 08.05. | Ono Pharmaceutical Co Ltd. Full Year Profit Climbs | 3 | RTTNews | ||
| 26.03. | Ono Pharma Submits Application For Manufacturing And Marketing Approval Of Ripretinib | 451 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical (4528.T) announced that it has submitted an application for the manufacturing and marketing approval of ripretinib or DCC-2618, developed... ► Artikel lesen | |
| 02.02. | Ono Pharmaceutical Co. Ltd. Reveals Climb In Nine Months Bottom Line | 538 | AFX News | TOKYO (dpa-AFX) - Ono Pharmaceutical Co. Ltd. (OPHLF) released a profit for its nine months that Increases, from the same period last yearThe company's earnings came in at JPY68.949 billion... ► Artikel lesen | |
| 14.01. | Ono Pharma Taiwan Receives Additional Approval Of Opdivo In Combination With Ipilimumab | 545 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Ono Pharmaceutical Co. announced that Ono Pharma Taiwan Co., a Taiwanese subsidiary of Ono, received the additional approval of Opdivo Intravenous Infusion... ► Artikel lesen | |
| 30.10.25 | Ono Pharmaceutical H1 Results Improve; Backs Annual Guidance | 554 | AFX News | TOKYO (dpa-AFX) - Ono Pharmaceutical Co., Ltd.(OPHLF, 4528.T) on Thursday reported a rise in earnings and revenue for the first half. In addition, the company has reaffirmed its annual outlook.For... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 125,44 | +0,26 % | Novo Nordisk gegen Eli Lilly, Johnson & Johnson setzt auf Zelltherapie - wo entsteht der nächste Milliardenmarkt? | ||
| CANOPY GROWTH | 0,900 | -1,29 % | Canopy Growth Corp (2): Canopy Growth mails proxy statements for AGSM | ||
| MERCK & CO | 130,78 | +0,14 % | Den Krebs im Fokus: Merck & Co., Vidac Pharma und AstraZeneca! | Aktuell gibt es laut der Internationalen Krebsforschungsagentur (IARC) der WHO rund 20,6 Millionen Krebsfälle. Die Zahl der Todesfälle wird auf jährlich etwa 10 Millionen Menschen geschätzt. In den... ► Artikel lesen | |
| JAGUAR HEALTH | 0,868 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Reports Second Quarter 2026 Financials | Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 446,00 | +0,72 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| IQVIA | 221,80 | -0,36 % | ROUNDUP: IQVIA Holdings Boosts FY26 Outlook; Shares Surge 10.6% | WASHINGTON (dpa-AFX) - While reporting financial results for the second quarter on Tuesday, life sciences services company IQVIA Holdings Inc. (IQV) raised its adjusted earnings and revenue... ► Artikel lesen | |
| AZENTA | 30,000 | -6,83 % | Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026. | BURLINGTON, Mass., Aug. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.
... ► Artikel lesen | |
| ALMIRALL | 10,580 | +0,19 % | Almirall, S.A.: Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology | The collaboration will leverage CrystalO's ion channel small-molecule drug discovery platform and Almirall's expertise in skin science to jointly advance an innovative small-molecule program in... ► Artikel lesen | |
| PROTHENA | 8,074 | -0,27 % | Prothena Corporation plc: Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months... ► Artikel lesen | |
| SPROUTLY CANADA | - | - | CSE Bulletin: Delist - Sproutly Canada Inc. (SPR) | Le 22 mai/May 2026
The common shares of Sproutly Canada Inc will be delisted from the CSE at market close today, May 22, 2026.
Sproutly Canada Inc. is currently suspended. See Bulletin 2022-0908.
___________________________
Les... ► Artikel lesen | |
| PETIQ | - | - | PetIQ Acquires MYOS To Expand Pet Muscle Health And Mobility Portfolio | ||
| FUJI PHARMA | 9,800 | -1,51 % | Dividendenbekanntmachungen (30.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 113 JPY 0,6124 EUR ACOM CO LTD JP3108600002 10 JPY 0,0542 EUR ADAMAS TRUST INC US6496048405 0,23 USD 0... ► Artikel lesen | |
| FINANCIERE DE TUBIZE | 187,40 | +0,16 % | Financière de Tubize SA: Financière de Tubize - 2026 half-year financial report | Half-year financial report 2026Regulated information 1 August 2026
The board of directors of Financière de Tubize has established the 2026 half-year report. This report is available on the website... ► Artikel lesen | |
| BAYER | 48,040 | -1,17 % | Bayer ist mehr als die Roundup-Wette | Bayer hat an der Börse lange fast nur über ein einziges Thema funktioniert: Glyphosat. Gute Pharmadaten, Agrarwachstum oder Sparprogramme wurden regelmäßig von neuen US-Rechtsrisiken überlagert. Im... ► Artikel lesen | |
| MERCK KGAA | 137,95 | -0,07 % | Bundeskartellamt gibt Übernahme von Bio-Techne durch Merck KGaA (Darmstadt) frei | Das Bundeskartellamt hat heute die geplante Übernahme des US-amerikanischen Biotechnologieunternehmens Bio-Techne, Minneapolis, durch die Merck KGaA aus Darmstadt freigegeben. Das Vorhaben ist auch... ► Artikel lesen |